ALNYLAM PHARMACEUTICALS, INC. ($ALNY)
Filing Information
| Accession Number | 0001735276-26-000050 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 5, 2026 |
| Document | View SEC Filing |
Transactions
12
Total Shares
16,847
Total Value
$523,583.78
P&L
+inf% (+$4,760,280.33)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Grant/Award | 4,769 | $0.00 | $0.00 | 38,204 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 47 | $323.62 | $15,210.14 | 38,157 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 90 | $324.65 | $29,218.50 | 38,067 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 258 | $325.63 | $84,012.54 | 37,809 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 392 | $326.81 | $128,109.52 | 37,417 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 329 | $327.67 | $107,803.43 | 37,088 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 100 | $328.71 | $32,871.00 | 36,988 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 170 | $329.71 | $56,050.70 | 36,818 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 81 | $330.85 | $26,798.85 | 36,737 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 94 | $331.93 | $31,201.42 | 36,643 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 37 | $332.64 | $12,307.68 | 36,606 | Direct | โ | View Details | |
EVP, Chief Commercial Officer | Stock Option (right to buy) | Derivative | Mar 2, 2026 | Grant/Award | 10,480 | $0.00 | $0.00 | 10,480 | Direct | โ | View Details |